Hepatitis C virus (HCV) infection is one of the major causes leading to orthotopic liver transplantation (OLT) worldwide. Although viral infection persists in almost all patients, the pathology of recurrent HCV infection after OLT is not well characterized. To address this issue, we compared the pat
Kinetics of hepatitis C virus reinfection after liver transplantation
โ Scribed by Kimberly A. Powers; Ruy M. Ribeiro; Keyur Patel; Stephen Pianko; Lisa Nyberg; Paul Pockros; Andrew J. Conrad; John McHutchison; Alan S. Perelson
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 230 KB
- Volume
- 12
- Category
- Article
- ISSN
- 1527-6465
- DOI
- 10.1002/lt.20572
No coin nor oath required. For personal study only.
โฆ Synopsis
Improved understanding of hepatitis C virus (HCV) dynamics during and after liver transplantation can be useful in optimizing antiviral therapy in transplant recipients. We analyzed serum HCV ribonucleic acid (RNA) levels during and after cadaveric liver transplantation in 6 HCV patients. After removal of the liver and before the new liver started producing virions, HCV RNA levels dropped with an average half-life (t 1/2 ) of 0.8 hours. Viral loads then continued to drop up to 23 hours postimplantation (t 1/2 ฯญ 3.4 hours), and began to rise (doubling-time ฯญ 2.0 days) as soon as 15 hours after the anhepatic phase. In 3 patients the viral load reached a plateau before rising, suggesting that a nonhepatic source supplied virions and balanced their intrinsic clearance. However, from the decline in viral load over the first 24 hours of the postanhepatic phase, we estimate that nonhepatic sources can at most correspond to 4% of total viral production, 96% of which occurs in the liver, even after we corrected for fluid exchanges during surgery. As the new liver was reinfected, production increased and viral load rose to a new steady state. Using nonlinear regression, we were able to fit the patients' HCV RNA data to a viral dynamic model and estimate the de novo infection rate (mean 1.5 ฯซ 10 ฯช6 mL/virion/day), as well as the average percentage of hepatocytes infected at the posttransplantation steady state (19%). In conclusion, we have quantified liver reinfection dynamics in the absence of posttransplantation antiviral therapy. Our findings support the notion that early antiviral therapy may delay or prevent reinfection.
๐ SIMILAR VOLUMES
## Identification of the hepatitis C virus-the main cause of posttransfusion and sporadic non -A, non-B hepatitisand the development of a diagnostic serological test have allowed us to study possible recurrence of this type of hepatitis after liver transplantation. Six of 34 consecutive transplant
1. Early recurrence of hepatitis C is universal. 2. Typical histopathologic features of hepatitis C virus (HCV) and acute allograft rejection (AAR) exist. 3. Early recurrent HCV may be differentiated from AAR. 4. Liver biopsy plays a role in diagnosing HCV and AAR. 5. Risk factors for recurrent HCV
Liver transplant recipients are a model of rapid progression of hepatitis C virus (HCV)-related liver disease, from normal to cirrhosis. The aim of the study was the analysis of the relationship between portohepatic hemodynamics and modification in liver histology during the progression of HCV liver
with treatment failures moving on to combination therapy (IFN/CMB). The primary difference between the two best strategies (IFN/CBM vs. CMB-G) was that the CMB-G strategy was more successful with those with genotype 1. Thus, the genotyping strategy reached more people with less responsive disease th
Chronic infection with the hepatitis C virus (HCV) is the most common reason for liver transplantation. We examined the results of laboratory tests for HCV on a cohort of patients who received a liver transplant between 1990 and 1994 at three large centers. Seven hundred twenty-two recipients and 60